Chongqing Zhifei Bio Products (300122.SZ) stock: key figures, P/E, revenue and dividend

Health Care · Biotechnology · China · ISIN CNE100000V20

Price

13.48 CNY

Market cap

32.27 bn CNY

P/E (2025)

–

P/S (2025)

3.60

Dividend yield

0.00 %

Net margin

-164.35 %

Return on equity (ROE)

-92.95 %

Return on assets (ROA)

-46.42 %

Chongqing Zhifei Bio Products financials

Fiscal year	2024	2025
Revenue	26.07 bn CNY	8.96 bn CNY
Gross profit	7.10 bn CNY	702.74 m CNY
Operating income	2.26 bn CNY	-3.02 bn CNY
EBIT	2.34 bn CNY	-17.16 bn CNY
Net income	2.02 bn CNY	-14.72 bn CNY
Diluted EPS – continuing operations	0.84 CNY	-6.15 CNY

Full history since 2007, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Chongqing Zhifei Bio Products

Chongqing Zhifei Biological Products Co., Ltd., a biopharmaceutical company, engages in the research and development, production, sale, and distribution of vaccine and biological products in China. The company offers recombinant COVID-19 vaccine; recombinant mycobacterium tuberculosis fusion protein products; group A and C meningococcal polysaccharide vaccine; ACYW135 meningococcal polysaccharide vaccine; Haemophilus Influenza type B conjugate vaccine; mycobacterium injection under the Vaccae brand; and meningococcal group A and C conjugate vaccine. It also provides cold storage, refrigerated vehicles, and cold roll boxes; and customs clearance and registration of imported vaccines. The company was founded in 2002 and is based in Chongqing, China.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 30.10.2026. Details in the risk notice.